Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma

Anthony P. Lam, Joseph A. Sparano, Vincent Vinciguerra, Allyson J. Ocean, Paul Christos, Howard Hochster, Fernando J. Camacho, Sanjay Goel, Sridhar Mani, Andreas Kaubisch

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: To determine the efficacy and toxicity of the protein kinase C inhibitor bryostatin-1 plus paclitaxel in patients with advanced pancreatic carcinoma. Methods: Each treatment cycle consisted of paclitaxel 90 mg/m by intravenous infusion over 1 hour on days 1, 8, and 16, plus bryostatin 25 mcg/m as a 1-hour intravenous infusion on days 2, 9, and 15, given every 28 days. Patients were evaluated for response after every 2 treatment cycles, and continued therapy until disease progression or prohibitive toxicity. The primary objective was to determine whether the combination produced a response rate of at least 30%. Results: Nineteen patients with locally advanced or metastatic pancreatic adenocarcinoma received a total of 52 cycles of therapy (range: 1-10). Patients received the combination as first-line therapy for advanced disease (N = 5) or after prior chemotherapy used alone or in combination with local therapy. No patients had a confirmed objective response. The median time to treatment failure was 1.9 months (95% confidence intervals: 1.2, 2.6 months). Reasons for discontinuing therapy included progressive disease or death in 14 patients (74%) or because of adverse events or patient choice in 5 patients (26%). The most common grade 3 to 4 toxicities included leukopenia in 26%, anemia in 11%, myalgias in 11%, gastrointestinal bleeding in 11%, infection in 10%, and thrombosis in 10%. Conclusion: The combination of weekly paclitaxel and bryostatin-1 is not an effective therapy for patients with advanced pancreatic carcinoma.

Original languageEnglish (US)
Pages (from-to)121-124
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume33
Issue number2
DOIs
StatePublished - Apr 2010

Fingerprint

Protein C Inhibitor
Protein Kinase Inhibitors
Paclitaxel
Protein Kinase C
Therapeutics
Intravenous Infusions
Pancreatic Carcinoma
bryostatin 1
Myalgia
Leukopenia
Treatment Failure
Disease Progression
Anemia
Adenocarcinoma
Thrombosis
Confidence Intervals
Hemorrhage
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. / Lam, Anthony P.; Sparano, Joseph A.; Vinciguerra, Vincent; Ocean, Allyson J.; Christos, Paul; Hochster, Howard; Camacho, Fernando J.; Goel, Sanjay; Mani, Sridhar; Kaubisch, Andreas.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 33, No. 2, 04.2010, p. 121-124.

Research output: Contribution to journalArticle

@article{3229250914a348ec877a6bf7b3e56eb7,
title = "Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma",
abstract = "Purpose: To determine the efficacy and toxicity of the protein kinase C inhibitor bryostatin-1 plus paclitaxel in patients with advanced pancreatic carcinoma. Methods: Each treatment cycle consisted of paclitaxel 90 mg/m by intravenous infusion over 1 hour on days 1, 8, and 16, plus bryostatin 25 mcg/m as a 1-hour intravenous infusion on days 2, 9, and 15, given every 28 days. Patients were evaluated for response after every 2 treatment cycles, and continued therapy until disease progression or prohibitive toxicity. The primary objective was to determine whether the combination produced a response rate of at least 30{\%}. Results: Nineteen patients with locally advanced or metastatic pancreatic adenocarcinoma received a total of 52 cycles of therapy (range: 1-10). Patients received the combination as first-line therapy for advanced disease (N = 5) or after prior chemotherapy used alone or in combination with local therapy. No patients had a confirmed objective response. The median time to treatment failure was 1.9 months (95{\%} confidence intervals: 1.2, 2.6 months). Reasons for discontinuing therapy included progressive disease or death in 14 patients (74{\%}) or because of adverse events or patient choice in 5 patients (26{\%}). The most common grade 3 to 4 toxicities included leukopenia in 26{\%}, anemia in 11{\%}, myalgias in 11{\%}, gastrointestinal bleeding in 11{\%}, infection in 10{\%}, and thrombosis in 10{\%}. Conclusion: The combination of weekly paclitaxel and bryostatin-1 is not an effective therapy for patients with advanced pancreatic carcinoma.",
author = "Lam, {Anthony P.} and Sparano, {Joseph A.} and Vincent Vinciguerra and Ocean, {Allyson J.} and Paul Christos and Howard Hochster and Camacho, {Fernando J.} and Sanjay Goel and Sridhar Mani and Andreas Kaubisch",
year = "2010",
month = "4",
doi = "10.1097/COC.0b013e3181a31920",
language = "English (US)",
volume = "33",
pages = "121--124",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma

AU - Lam, Anthony P.

AU - Sparano, Joseph A.

AU - Vinciguerra, Vincent

AU - Ocean, Allyson J.

AU - Christos, Paul

AU - Hochster, Howard

AU - Camacho, Fernando J.

AU - Goel, Sanjay

AU - Mani, Sridhar

AU - Kaubisch, Andreas

PY - 2010/4

Y1 - 2010/4

N2 - Purpose: To determine the efficacy and toxicity of the protein kinase C inhibitor bryostatin-1 plus paclitaxel in patients with advanced pancreatic carcinoma. Methods: Each treatment cycle consisted of paclitaxel 90 mg/m by intravenous infusion over 1 hour on days 1, 8, and 16, plus bryostatin 25 mcg/m as a 1-hour intravenous infusion on days 2, 9, and 15, given every 28 days. Patients were evaluated for response after every 2 treatment cycles, and continued therapy until disease progression or prohibitive toxicity. The primary objective was to determine whether the combination produced a response rate of at least 30%. Results: Nineteen patients with locally advanced or metastatic pancreatic adenocarcinoma received a total of 52 cycles of therapy (range: 1-10). Patients received the combination as first-line therapy for advanced disease (N = 5) or after prior chemotherapy used alone or in combination with local therapy. No patients had a confirmed objective response. The median time to treatment failure was 1.9 months (95% confidence intervals: 1.2, 2.6 months). Reasons for discontinuing therapy included progressive disease or death in 14 patients (74%) or because of adverse events or patient choice in 5 patients (26%). The most common grade 3 to 4 toxicities included leukopenia in 26%, anemia in 11%, myalgias in 11%, gastrointestinal bleeding in 11%, infection in 10%, and thrombosis in 10%. Conclusion: The combination of weekly paclitaxel and bryostatin-1 is not an effective therapy for patients with advanced pancreatic carcinoma.

AB - Purpose: To determine the efficacy and toxicity of the protein kinase C inhibitor bryostatin-1 plus paclitaxel in patients with advanced pancreatic carcinoma. Methods: Each treatment cycle consisted of paclitaxel 90 mg/m by intravenous infusion over 1 hour on days 1, 8, and 16, plus bryostatin 25 mcg/m as a 1-hour intravenous infusion on days 2, 9, and 15, given every 28 days. Patients were evaluated for response after every 2 treatment cycles, and continued therapy until disease progression or prohibitive toxicity. The primary objective was to determine whether the combination produced a response rate of at least 30%. Results: Nineteen patients with locally advanced or metastatic pancreatic adenocarcinoma received a total of 52 cycles of therapy (range: 1-10). Patients received the combination as first-line therapy for advanced disease (N = 5) or after prior chemotherapy used alone or in combination with local therapy. No patients had a confirmed objective response. The median time to treatment failure was 1.9 months (95% confidence intervals: 1.2, 2.6 months). Reasons for discontinuing therapy included progressive disease or death in 14 patients (74%) or because of adverse events or patient choice in 5 patients (26%). The most common grade 3 to 4 toxicities included leukopenia in 26%, anemia in 11%, myalgias in 11%, gastrointestinal bleeding in 11%, infection in 10%, and thrombosis in 10%. Conclusion: The combination of weekly paclitaxel and bryostatin-1 is not an effective therapy for patients with advanced pancreatic carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=77951078231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951078231&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181a31920

DO - 10.1097/COC.0b013e3181a31920

M3 - Article

C2 - 19738452

AN - SCOPUS:77951078231

VL - 33

SP - 121

EP - 124

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -